HOME >> BIOLOGY >> NEWS
Boston hospitals report early results of endostatin clinical trial

Information from phase I trial reported today in Amsterdam

BOSTON--Clinical researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital, Brigham and Women's Hospital and Beth Israel Deaconess Medical Center today presented preliminary information from their Phase I clinical trial of Endostatin™ Protein, an angiogenesis inhibitor that seeks to reduce tumors by cutting off their blood supply.

Early results from 19 patients treated in the Boston clinical trial were reported in Amsterdam at the Symposium on New Drugs in Cancer Therapy sponsored by the National Cancer Institute, European Organization for Research and the Treatment of Cancer and American Association of Cancer Research. Results from patients treated in Texas and Wisconsin were also reported at the conference being held November 7 - 10.

"Endostatin is safe and well-tolerated in high doses without any evidence of toxicity," said Donald Kufe, MD, principal investigator of the Harvard hospital clinical trial. "Extended periods of stable disease and minor responses have been demonstrated; however, these are early results and further study is needed to determine just how effective this therapy will be over time."

The Boston hospitals were the first to begin testing of the Endostatin Protein in patients in fall 1999. Since then, 19 patients have been enrolled in the Boston portion of this Phase I trial. Two patients in Boston are currently receiving treatment and twelve patients were taken off the study due to disease progression. The remaining patients voluntarily withdrew from the study.

Of the patients being reported on in Europe, four were diagnosed with breast cancer, three with lung cancer, three with colon cancer, two with pancreatic cancer, two with neuro-endocrine tumors, two with sarcoma, and three with other forms of cancer.

"It is too early to assess the clinical significance of Endostatin's effectiveness based on this preliminary
'"/>

Contact: Todd Ringler
todd_ringler@dfci.harvard.edu
617-632-4090
Dana-Farber Cancer Institute
8-Nov-2000


Page: 1 2

Related biology news :

1. Springtime blooms seen earlier now than in the past, say Boston University biologists
2. Childrens Hospital Boston receives more than $10 million to help make smallpox vaccine safer
3. NIH funds new Boston College-Boston University study of B-1a cell associated with leukemia
4. The American Society for Biochemistry and Molecular Biology meets in Boston
5. Boston chemist wins national award for research with enzymes, antibiotics
6. Boston chemist wins national award for protein research
7. Tufts civil engineer predicts Bostons rising sea levels could cause billions of dollars in damage
8. Childrens Hospital Boston researchers regenerate zebrafish heart muscle
9. Microorganisms are cleaning up Boston Harbor, UMass study finds
10. Highlights of American Chemical Societys national meeting in Boston
11. Childrens Hospital Boston researchers use therapeutic cloning to create functional tissue in cows

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
Cached News: